Zensar acquires BridgeView Life Sciences to boost healthcare and life sciences focus

Zensar Technologies, an RPG Group Company headquartered in Pune, India, and a leading experience, engineering, and engagement technology solutions company, announced today the full acquisition of BridgeView Life Sciences LLC. The US‐based leader in information technology and operations provides a comprehensive range of advisory, transformation, and managed services exclusively for life sciences customers endeavoring to launch products or new indications, assess and optimize their operations, or engage in merger or acquisition transactions. This strategic move strengthens Zensar's Healthcare and Life Sciences (HLS) vertical and expands its pharma commercial and product launch expertise.

The acquisition positions Zensar to offer a more comprehensive suite of solutions to pharmaceutical, biotechnology, and medical device companies. BridgeView's "Preferred Services Partner" and "Services Partner" status with Veeva Systems' Commercial Cloud and Development Cloud, respectively, solidify Zensar's position as a trusted technology partner. Additionally, BridgeView's partnerships with Reltio, Datavant, Snowflake, Salesforce, and IQVIA bolster its capabilities.

Commenting on this acquisition, Anant Goenka, Vice‐Chairman of RPG Enterprises and Zensar Technologies, said, "Acquiring BridgeView Life Sciences aligns with our long‐term growth strategy for our growing HLS practice. This acquisition deepens ourservicesfor existing clients and expandsinto new areas, especially for innovators and emerging pharma players underserved by technology. It reflects our commitment to anticipating client and market needs and providing solutions to critical challenges."

The acquisition positions Zensar as a pivotal force in driving innovation and facilitating the digital transformation of life sciences companies, effectively addressing the industry's key challenges.

Manish Tandon, CEO and Managing Director of Zensar Technologies, said, "BridgeView Life Sciences brings a team ofseasoned professionals with deep life sciences knowledge and a successful track record. This aligns perfectly with our vision to be a leader in the HLS space. BridgeView's expertise in biopharma cloud CRM, information management, analytics, and program management combined with their established client base will significantly enhance our HLS offerings and accelerate our go‐to‐market strategy."

James Corbett, Co‐founder and COO, and Mihales Karasavas, Co‐founder and CCO of BridgeView Life Sciences LLC, stated, "We are thrilled to join Zensar. Zensar's global reach and digital expertise will help us offer more solutions and reach a wider audience. This synergy allows us to address customers' transformational programs effectively, improving patient lives faster. We look forward to a bright future together."

Everest Group's Veeva Services PEAK Matrix® Assessment 2021 predicted the Veeva‐specific IT services market to reach US $2 billion by 2025. This acquisition positions Zensar to capitalize on this rapidly growing opportunity with a combined team dedicated to delivering superior Veeva solutions such as Veeva Network, Veeva Vault, and Vault CRM.

Shares of Zensar Technologies Limited was last trading in BSE at Rs. 778.85 as compared to the previous close of Rs. 787.10. The total number of shares traded during the day was 101877 in over 6275 trades.

The stock hit an intraday high of Rs. 803.95 and intraday low of 775.05. The net turnover during the day was Rs. 79957506.00.

Source : Equity Bulls

Keywords

ZensarTechnologies INE520A01027 Acquisition LifeSciences Healthcare BridgeVIewLifeSciencesLLC